AMLX · Amylyx Pharmaceuticals, Inc. · Documents
$28.77
+1.44 (+5.27%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$3.22B
Shares
111.42M
Volume · Oct 20
1.61M
Avg daily vol (3M)
2.32M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | — | 2024-04-10 | — | |
| 8-K | — | 2024-04-04 | 2024-04-03 | |
| 8-K | — | 2024-03-14 | — | |
| 8-K | — | 2024-03-08 | — | |
| 8-K | — | 2024-02-22 | — | |
| 10-K | — | 2024-02-22 | 2023-12-31 | |
| 8-K | — | 2023-12-07 | — | |
| 10-Q | — | 2023-11-09 | 2023-09-30 | |
| 8-K | — | 2023-11-09 | — | |
| 8-K | — | 2023-10-13 | — | |
| 10-Q | — | 2023-08-10 | 2023-06-30 | |
| 8-K | — | 2023-08-10 | — | |
| 8-K | — | 2023-07-26 | — | |
| 8-K | — | 2023-06-23 | — | |
| 8-K | — | 2023-06-09 | 2023-06-08 | |
| 8-K | — | 2023-05-11 | — | |
| 10-Q | — | 2023-05-11 | 2023-03-31 | |
| ARS | — | 2023-04-27 | 2022-12-31 | |
| DEFA14A | — | 2023-04-27 | — | |
| DEF 14A | — | 2023-04-27 | 2023-06-08 | |
| 8-K | — | 2023-03-21 | 2023-03-13 | |
| 8-K | — | 2023-03-13 | — | |
| 10-K | — | 2023-03-13 | 2022-12-31 | |
| S-3ASR | — | 2023-03-13 | — | |
| 8-K | — | 2023-02-14 | — | |
| 8-K | — | 2022-12-06 | 2022-12-01 | |
| 10-Q | — | 2022-11-10 | 2022-09-30 | |
| 8-K | — | 2022-11-10 | — | |
| 8-K | — | 2022-11-02 | 2022-11-01 | |
| S-1 | — | 2022-10-04 | — | |
| 8-K | — | 2022-09-30 | — | |
| 10-Q | — | 2022-08-11 | 2022-06-30 | |
| 8-K | — | 2022-08-11 | — | |
| 8-K | — | 2022-08-11 | — | |
| 8-K | — | 2022-07-05 | — | |
| 8-K | — | 2022-06-13 | — | |
| 8-K | — | 2022-06-09 | — | |
| 8-K | — | 2022-06-03 | — | |
| 10-Q | — | 2022-05-12 | 2022-03-31 | |
| 8-K | — | 2022-05-12 | — | |
| DEF 14A | — | 2022-04-29 | 2022-06-09 | |
| DEFA14A | — | 2022-04-29 | — | |
| 10-K | — | 2022-03-31 | 2021-12-31 | |
| 8-K | — | 2022-03-31 | 2022-03-30 | |
| 8-K | — | 2022-01-11 | — | |
| S-1/A | — | 2022-01-03 | — | |
| S-1 | — | 2021-12-16 | — |
Showing 51–97 of 97 filings
Key facts
CIK
1658551
CUSIP
03237H101
13F (30d)
13 filings
13 filers
Visit website
Investor relations